Cmbio® Expands Digital Biology Platform Through Acquisition of Eagle Genomics' Assets
In a significant move to bolster its leadership in the multi-omics and digital biology domain, Cmbio®, a prominent player on the global stage, has successfully acquired the intellectual property and assets of Eagle Genomics. This acquisition comes as part of an Asset Sale Agreement with CBW Recovery LLP and Eagle Genomics Limited, the latter being renowned for its cutting-edge enterprise cloud software platform. Based in Cambridge, UK, Eagle Genomics has made a name for itself by providing tools that enable researchers to curate, share, and analyze complex scientific data effectively.
The e[datascientist]™ software platform, a key component in this acquisition, promises to enhance the functionality of Cmbio®’s existing digital biology solutions. As scientists in various fields increasingly rely on robust data sets for their research, Cmbio® recognizes the importance of integrating advanced bioinformatics tools and AI/ML technologies into their offerings. Anders Grøn, CEO of Cmbio®, stated that this acquisition underscores the company's commitment to delivering scalable multi-omics solutions that meet the evolving demands of the scientific community.
Cmbio®, which has a robust foundation in multi-omics science, aims to make substantial strides through this integration. By combining the strengths of Eagle Genomics’ innovative platform with their own operational capabilities, Cmbio® is set to provide unparalleled access to tools that support advanced research initiatives. The strategic acquisition is about more than just software; it represents a broader vision to support discoveries in microbiome research, genomics, and other fields that benefit from data-driven insights.
The history of Eagle Genomics dates back to 2008, when it was founded with the mission of empowering life sciences organizations to harness the potential of their scientific data. Their platform has not only helped in the curation and integration of data but has also advanced the analysis processes that lead to significant breakthroughs in research.
Both Cmbio® and Eagle Genomics share a common objective: to promote the understanding of the microbiome's influence on health, extending benefits to humans, animals, and the planet. By integrating their technologies, Cmbio® strengthens its already impressive portfolio, facilitating more comprehensive research services capable of addressing complex biological questions.
With this move, Cmbio® continues to position itself as a preferred partner in multi-omics services globally. Manoj Dadlani, Chairman of Cmbio®, emphasized this commitment, stating that the addition of Eagle Genomics' platform complements their existing technology suite developed from years of experience in the multi-omics arena. The acquisition reflects a forward-thinking approach aimed at meeting the future demands of digital biology, fostering collaboration among researchers across the industry and academia.
As Cmbio® moves forward, it builds upon a legacy of significant research contributions, having supported over 1,000 studies related to the microbiome across diverse fields of health. The integration with Eagle Genomics will undoubtedly accelerate the pace of innovation within the company and reinforce its status as a leading player in the digital biology landscape.
In summary, Cmbio®'s acquisition of Eagle Genomics’ assets marks a pivotal moment for the company, allowing it to enhance its multi-omics software and AI/ML capabilities. This strategic step not only enriches Cmbio®’s technological offerings but also aligns with its overarching mission to advance scientific understanding and improve health outcomes globally.
The e[datascientist]™ software platform, a key component in this acquisition, promises to enhance the functionality of Cmbio®’s existing digital biology solutions. As scientists in various fields increasingly rely on robust data sets for their research, Cmbio® recognizes the importance of integrating advanced bioinformatics tools and AI/ML technologies into their offerings. Anders Grøn, CEO of Cmbio®, stated that this acquisition underscores the company's commitment to delivering scalable multi-omics solutions that meet the evolving demands of the scientific community.
Cmbio®, which has a robust foundation in multi-omics science, aims to make substantial strides through this integration. By combining the strengths of Eagle Genomics’ innovative platform with their own operational capabilities, Cmbio® is set to provide unparalleled access to tools that support advanced research initiatives. The strategic acquisition is about more than just software; it represents a broader vision to support discoveries in microbiome research, genomics, and other fields that benefit from data-driven insights.
The history of Eagle Genomics dates back to 2008, when it was founded with the mission of empowering life sciences organizations to harness the potential of their scientific data. Their platform has not only helped in the curation and integration of data but has also advanced the analysis processes that lead to significant breakthroughs in research.
Both Cmbio® and Eagle Genomics share a common objective: to promote the understanding of the microbiome's influence on health, extending benefits to humans, animals, and the planet. By integrating their technologies, Cmbio® strengthens its already impressive portfolio, facilitating more comprehensive research services capable of addressing complex biological questions.
With this move, Cmbio® continues to position itself as a preferred partner in multi-omics services globally. Manoj Dadlani, Chairman of Cmbio®, emphasized this commitment, stating that the addition of Eagle Genomics' platform complements their existing technology suite developed from years of experience in the multi-omics arena. The acquisition reflects a forward-thinking approach aimed at meeting the future demands of digital biology, fostering collaboration among researchers across the industry and academia.
As Cmbio® moves forward, it builds upon a legacy of significant research contributions, having supported over 1,000 studies related to the microbiome across diverse fields of health. The integration with Eagle Genomics will undoubtedly accelerate the pace of innovation within the company and reinforce its status as a leading player in the digital biology landscape.
In summary, Cmbio®'s acquisition of Eagle Genomics’ assets marks a pivotal moment for the company, allowing it to enhance its multi-omics software and AI/ML capabilities. This strategic step not only enriches Cmbio®’s technological offerings but also aligns with its overarching mission to advance scientific understanding and improve health outcomes globally.
Topics Consumer Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.